Is There Currently a Place for Combined Mitral and Aortic Transcatheter Interventions?
Purpose of Review
The goal was to evaluate published data on the incidence, diagnosis, and management of symptomatic combined mitral and aortic valvular disease. Furthermore, to identify the role of treatment using contemporary transcatheter techniques.
Up to a quarter of symptomatic adult valvular disease is caused by multiple left-sided valvular lesions. The etiologic spectrum of this combined disease has shifted from rheumatic to degenerative. Both presentation and diagnosis of lesions are modified compared with isolated disease. Based upon narrative review, there are only limited observational experiences, insufficient to provide robust guidance. These data, however, indicate the feasibility of interventions such as transcatheter aortic valve replacement and edge-to-edge mitral valve repair to treat such disease and mitigate the risks of open surgery.
Combined aortic and mitral valve disease is commonly encountered. There is a role for transcatheter interventions based on limited data; however, more research is needed.
KeywordsMultivalve Multiple valve disease Combined valve disease Transcatheter intervention
Compliance with Ethical Standards
Conflict of Interest
Rodney De Palma, Crochan J. O’Sullivan, and Magnus Settergren declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.• Valvular Heart Disease II (VHDII) Survey (European Society of Cardiology website). 2018. Available at: https://esc365.escardio.org/Congress/ESC-Congress-2018/Late-Breaking-Registry-Results-1/181465-eorp-vhd-ii-registry-contemporary-mangement-of-heart-valve-disease (accessed 28th September 2018). Cross-sectional survey of valvular disease in Europe.
- 9.•• Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017;30:303–71. Comprehensive document detailing the strengths and limitations of echocardiography and cardiac magnetic resonance in evaluating valvular disease.CrossRefGoogle Scholar
- 14.•• Ando T, Takagi H, Briasoulis A, Telila T, Slovut DP, Afonso L, et al. A systematic review of reported cases of combined transcatheter aortic and mitral valve interventions. Catheter Cardiovasc Interv. 2018;91:124–34. A recent systematic review of 37 studies comprising 60 patients of combined transcatheter intervention for aortic and mitral valve disease.CrossRefGoogle Scholar
- 15.• Vollenbroich R, Stortecky S, Praz F, Lanz J, Franzone A, Zuk K, et al. The impact of functional vs degenerative mitral regurgitation on clinical outcomes among patients undergoing transcatheter aortic valve implantation. Am Heart J. 2017;184:71–80. Registry data illustrating the poor prognosis of persistent severe degenerative mitral regurgitation after TAVR for aortic stenosis.CrossRefGoogle Scholar
- 17.Amat-Santos IJ, Castrodeza J, Nombela-Franco L, Muñoz-García AJ, Gutiérrez-Ibanes E, de la Torre Hernández JM, et al. Tricuspid but not mitral regurgitation determines mortality after TAVI in patients with nonsevere mitral regurgitation. Rev Esp Cardiol (Engl Ed). 2018;71:357–64.CrossRefGoogle Scholar
- 20.•• Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2018. https://doi.org/10.1056/NEJMoa1805374. Randomised data in 150 patients demonstrating similar mortality and unscheduled hospitalisation for heart failure outcomes with percutaneous edge-to-edge repair and medical therapy for moderate-severe functional mitral regurgitation compared with medical therapy alone at 1 year.CrossRefGoogle Scholar
- 21.•• Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379:2307–18. Randomised data in 614 patients with moderate-severe functional MR showing a reduction in mortality and heart failure hospitalisations with a large effect size at 2 years.CrossRefGoogle Scholar
- 23.•• Joseph L, Bashir M, Xiang Q, Yerokun BA, Matsouaka RA, Vemulapalli S, et al. Prevalence and outcomes of mitral stenosis in patients undergoing transcatheter aortic valve replacement: findings from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry. JACC Cardiovasc Interv. 2018;11:693–702. United States registry data describing combined aortic and mitral stenoses in up to 12% of patients and associated with worse clinical outcomes than isolated left-sided valvular disease.CrossRefGoogle Scholar
- 29.• Silaschi M, Conradi L, Wendler O, Schlingloff F, Kappert U, Rastan AJ, et al. The JUPITER registry: one-year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation. Catheter Cardiovasc Interv. 2018;91:1345–51. Registry data with short-medium term follow-up for the use of a dedicated transapical valve for severe aortic regurgitation.CrossRefGoogle Scholar
- 32.• Del Val D, Regueiro A, Rodríguez-Gabella T, Paradis JM, Puri R, Rodés-Cabau J. Concomitant or staged transcatheter treatment for severe combined aortic and mitral valve disease. Rev Esp Cardiol (Engl Ed). 2018;71:676–9. Systematic review describing the safety and feasibility of combined transcatheter intervention for severe aortic stenosis and mitral regurgitation.CrossRefGoogle Scholar
- 37.Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2012;42:S1–44.CrossRefGoogle Scholar
- 38.• Alame AJ, Karatasakis A, Karacsonyi J, Danek BA, Sorajja P, Gössl M, et al. Comparison of the American College of Cardiology/American Heart Association and the European Society of Cardiology Guidelines for the Management of Patients With Valvular Heart Disease. J Invasive Cardiol. 2017;29:320–6. A paper describing both North American and European valvular disease management guidelines and focussing on their differences.PubMedGoogle Scholar
- 39.Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70:252–89.CrossRefGoogle Scholar